Rejected at 2:44 p.m. May, 23, 2024 ] by beejumm
Author: gokul123
Related Note: 1481331078662 1
Rationale for change

"massive splenomegaly" is a redundancy. Massive can be deleted and the cloze 1 can read "[pathology]" As in:

Myelofibrosis is often associated with {{c1:pathology?::splenomegaly}} due to extramedullary hematopoiesis

Rejection reason

Massive splenomegaly is defined as a palpable spleen more than 8 cm below costal arch, > 20 cm in diameter, and/or weight > 1000 g

https://next.amboss.com/us/article/KT0U72?q=massive%20splenomegaly#XJX9s_

Text Text
Extra
Empty field
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Sketchy Extra
Empty field
Picmonic
Empty field
Pixorize
Empty field
Physeo
Empty field
Bootcamp
OME
Additional Resources
One by one
Empty field
#AK_Step1_v12::^Systems::HemeOnc::WBC #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::03_Myeloproliferative_Disorders::04_Primary_Myelofibrosis #AK_Step1_v12::#UWorld::COMLEX::25954 #AK_Step2_v12::#SketchyIM::10_Gastroenterology::01_Approach_to_Abdominal_Pain::01_Upper_Abdominal_Pain_DDx #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::05_Bone_Marrow_Failure::01_Bone_Marrow_Failure_DDx #AK_Step2_v12::#Resources_by_rotation::IM::ome::heme/onc::leukemia #AK_Step1_v12::#Pathoma::06_WBC::04_Myeloproliferative #AK_Step2_v12::#OME::01_Medicine::05_Hematology_Oncology::05_Leukemia #AK_Step1_v12::#UWorld::Step::14816 #AK_Step1_v12::#SketchyPath::10_Myeloid_&_Lymphoid::01_Myeloid_Disorders::01_Myeloproliferative_Neoplasms_&_Myelodysplastic_Syndromes #AK_Step2_v12::#AMBOSS::bF0Hg3 #AK_Step1_v12::#NBME::18 #AK_Step2_v12::!Shelf::IM::no_dupes #AK_Step2_v12::#COMBANK::53362 #AK_Step1_v12::#OME::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::02_Myeloproliferation #AK_Step2_v12::#B&B::07_Hematology_and_Oncology::03_White_Cells::02_Myeloproliferative_Disorders #AK_Other::#AK_Original_Decks::Step_1::Zanki_Step_Decks::Zanki_Hematology_&_Oncology::Pathoma_WBC #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::29_Myeloproliferative_neoplasms::03_Myelofibrosis #AK_Step2_v12::#SketchyIM::08_Hematology_&_Oncology::03_Myeloproliferative_Disorders::01_Myeloproliferative_Disorders_Overview #AK_Step1_v12::#B&B::12_Hematology::03_White_Blood_Cells::07_Myeloproliferative_Disorders #AK_Step1_v12::#Low/HighYield::4-LowerYield #AK_Step1_v12::#FirstAid::10_Hematology_and_Oncology::04_Pathology::29_Myeloproliferative_neoplasms #AK_Step1_v12::#OME::Clinical::04_Organ_Systems::05_Hematology_Oncology::04_Proliferation::02_Myeloproliferation #AK_Step1_v12::#Bootcamp::Hematology_and_Oncology::10_Plasma_Cell_Dyscrasias_&_Myeloproliferative_Disease::04_Myelofibrosis_and_Myelodysplastic_Syndromes #AK_Step1_v12::#Physeo::11_Pathology::10_HemeOnc_Pathology::14_Myeloproliferative_Disorders #AK_Step1_v12::#AMBOSS::rB0fXi #AK_Step2_v12::Original_decks::Dorian::im::ome::heme/onc::leukemia